Melbourne, Australia – 24 April 2020: Adherium (ASX:ADR) today announced the promotion of Mr Mike Motion from Chief Operating Officer to the role of Chief Executive Officer, replacing Mr Jeremy Curnock Cook who has held the position on an interim basis. Mike will also join the Board as an Executive Director, and Mr Curnock Cook will continue as a non-executive director. Ms. Anne Bell also joins the business today as Chief Financial Officer. The Board would like to thank and recognise Jeremy for his support and commitment to the business and continued contributions to the Board in his non-executive capacity.
“I am pleased to announce Mike’s promotion to the role of Chief Executive and welcome him to the
Board as a Director. Having worked closely with Mike over the last few months I am confident he can effectively lead the Adherium business. Mike has played a key role since joining Adherium in
November including the re-financing activity alongside the refresh of strategy, business model,
technology development plan and organization. Mike has also brought his network, energy and
focus to the acceleration of new partnering activities particularly in the US.
I am also pleased that Anne has accepted the offer to join the business as CFO reporting to Mike
based in Melbourne. Anne has a very strong background in finance, commerce and business
management and will be a strong addition to Adherium as an enterprise leader.
Anne’s appointment marks an important step as we further strengthen our corporate activities in
Australia and follows the recent announcement of the investment being made in software and
device development with Planet Innovation in Melbourne” said James Ward-Lilley, Chairman.
“I am delighted to take on the role of CEO for Adherium and lead the team to success as we execute
our strategy which will deliver shareholder value and improve patients’ lives. This is an exciting time
for Adherium given the increased focus on telehealth coming alongside reimbursement for remote
patient monitoring now in place in the USA. Adherium has a new team implementing a focused,
market relevant, provider value driven strategy and a clear development roadmap to re-establish
market leadership in inhaled medication device coverage including physiological data reporting. The
business is already making great progress as seen in our recent partnering announcement with HGE
and we look forward to providing further promising newsflow” said Mike Motion.
“It is a pleasure to join Adherium at such an exciting transformational stage and one where I can
apply my experience and best practices to a small business in a rapid growth phase. I look forward to
engaging with investors. With the increased emphasis in the development of our business in
Melbourne it is a great opportunity to provide local leadership to the Adherium team” said Anne
About Mike Motion
Mike has over 35 years’ corporate experience in medical devices and pharmaceuticals starting his
commercial career at Baxter Healthcare in 1984 working in manufacturing, sales and marketing and
commercial leadership roles at UK, European and global levels. This was across several therapeutic
areas including nutrition, infectious diseases and oncology.
Mike joined Biocompatibles in 2005 to lead the commercialisation of its Interventional Oncology
portfolio, setting up a direct sales force in the US and a global network of distributors in EMEA,
APAC, China and Japan. After growing the business to about US$40m per annum, Biocompatibles
was acquired by BTG in 2011 for US$283m. At BTG Mike held senior leadership roles as General
Manager for Interventional Oncology and Head of Digital Innovation, developing and executing
BTG’s digital health strategy in the therapeutic areas of oncology, anti-venom, vascular disease and
respiratory. Latterly, Mike was Head of Varithena, the only NDA approved treatment for Chronic
Venous Insufficiency, securing CPT coding and extensive payer coverage ahead of successful
commercialisation in the US. Mike graduated in Aberdeen, Scotland with a BSc in Pharmacy.
About Anne Bell
Anne is Australian and a qualified Chartered Accountant with strong executive global pharmaceutical leadership roles in AstraZeneca 2003-2008 and Menarini Group 2011-2018. Prior to Menarini Anne was the CFO for Invida which was subsequently acquired by Menarini in 2011.
Anne qualified as a chartered accountant in 1984 with Arthur Young before joining Arthur Andersen
becoming a partner in the Business Consulting practice. In 1996 she joined Colonial as Head of
Strategy Delivery which company was subsequently acquired by the Commonwealth Bank of
After the acquisition, Anne moved to become Vice President of Finance, Planning and Business
Development for the resort and travel business RCI, a subsidiary of Cendant, before joining
AstraZeneca as Regional Finance Director in Singapore in 2004.
Anne is a fellow the Institute of Chartered Accountants Australia and New Zealand and a Graduate of the Australian Institute of Company Directors.
About Adherium (ASX: ADR)
Adherium is a provider of digital health solutions and a global leader in connected respiratory
medical devices, with more than 170,000 sold globally. The company develops, manufactures and
supplies a broad range of connected medical devices for respiratory medications for patients,
pharmaceutical companies, healthcare providers and contract research organisations. Adherium’s
Hailie™ solution is designed to help patients achieve better adherence and provide visibility to
parents and caregivers. It does this by tracking medication use and reminding the user with helpful
nudges when it is time to take doses, and by providing access to usage history to better understand
patterns in their asthma and COPD. These tools ultimately enable people who live with asthma or
COPD to more easily manage their condition alongside their physician. Learn more at adherium.com.
The release of this announcement was authorised by the Adherium Board of Directors.
Enquiries: Rudi Michelson Mike Motion
Monsoon Communications Adherium
+61 3 9620 3333 +44 7917 688801
+61 (0)411 402 737